Medical technology company SIG.NUM benefits from a major investment from Anges Québec members and Anges Québec Capital
December 5, 2017
Montreal, December 5, 2017 – Anges Québec announced today a significant investment in SIG.NUM, a Montreal-based medtech startup that specializes in electrocardiography (ECG). Involving 10 investor members of Anges Québec as well as the Anges Québec Capital fund, which financially supports the members of the Anges Québec network, this fourth round of investment in SIG.NUM will support the company’s initial entry into the Canadian market as well as into targeted sites in the U.S. and Europe.
“At SIG.NUM, our vision is to create a new standard of care by making medical-grade ECGs more autonomous and accessible than ever before, allowing individuals to self-monitor anywhere, anytime. It is an honour to receive support from investor members of Anges Québec and Anges Québec Capital. With their valuable help, we will remove obstacles for patients by introducing a game-changing solution in cardiovascular health”, said David Nadezhdin, CEO and co-founder of SIG.NUM.
Democratizing cardiovascular health
SIG.NUM has developed an economical, contactless cardiac monitoring system that is as effective as a hospital or physician office system, with no impact on patient lifestyle. The technology significantly improves how cardiovascular diseases are defined, monitored and treated.
“SIG.NUM’s technology has the potential to become a revolutionary and essential cardiovascular health tool. Thanks to David Nadezhdin and SIG.NUM co-founder Dr. Deepak Bobby Jain’s instincts, expertise and vision, their system could help screen and treat cardiovascular diseases earlier and save lives as a result”, said Jean-François Grenon, lead angel for this investment round and company director in the technology sector.
“This new round of investment is a vote of confidence for David Nadezhdin, an exceptionally brilliant entrepreneur, and his company. The system developed by SIG.NUM is truly an innovative and disrupting solution, which is why Anges Québec Capital is delighted to help SIG.NUM market its ECG acquisition system and build on its extremely promising technological potential”, said Kalthoum Bouacida, Vice-President, Investment at Anges Québec Capital.
SIG.NUM manufactures a contactless ECG acquisition system that is used in both the consumer and medical markets. Its upcoming cloud-based platform will democratize cardiovascular health by recognizing and diagnosing early-stage diseases. The company was founded by David Nadezhdin and Dr. Deepak Bobby Jain in July 2014 and is headquartered in Montreal.
About Anges Québec Capital
Anges Québec Capital is an investment fund created to financially support the members of the Anges Québec network. Sponsored mainly by Investissement Québec, Caisse de dépôt et placement du Québec and Fonds de solidarité FTQ, the fund supports financial angels who invest in innovating start-ups, with $86M put at the disposal of entrepreneurs, allowing them to benefit from more substantial financial leverage in order to considerably increase the development of their enterprise.
About the Lead Angel
Jean-François Grenon, MBA has over 33 years of experience in the technology sector in the United States, Europe and Canada. He has designed and launched various innovative technical products and services on the global market, created several SMEs and has executed numerous mergers and acquisitions. As the head of Innova Corporation, he took the company public (NASDAQ) in 1997 and merged it with Digital Microwave Corporation in 1998. Mr. Grenon has a degree in electrical engineering from the École Polytechnique and has an MBA from the Harvard Business School.
Information and interviews: